<?xml version="1.0" encoding="UTF-8"?>
<study api_version="0.6">
  <id>1782</id>
  <name>UK10K_COHORT_ALSPAC</name>
  <active>true</active>
  <user_id>82</user_id>
  <followers>
    <follower>
      <login>tt3</login>
      <email>tt3@sanger.ac.uk</email>
      <name>Tere Tait</name>
      <id>425</id>
    </follower>
    <follower>
      <login>elg</login>
      <email>elg@sanger.ac.uk</email>
      <name>Emma Gray</name>
      <id>236</id>
    </follower>
  </followers>
  <managers>
    <manager>
      <login>jws</login>
      <email>jws@sanger.ac.uk</email>
      <name>James Stalker</name>
      <id>82</id>
    </manager>
  </managers>
  <owners>
    <owner>
      <login>jws</login>
      <email>jws@sanger.ac.uk</email>
      <name>James Stalker</name>
      <id>82</id>
    </owner>
  </owners>
  <!-- Family has been deprecated -->
  <family_id></family_id>
  <created_at>2011-03-14 11:19:25 +0000</created_at>
  <updated_at>2011-08-16 14:03:23 +0100</updated_at>
  <descriptors>
    <descriptor>
      <name>How is the data release to be timed?</name>
      <value>standard</value>
    </descriptor>
    <descriptor>
      <name>Has the delay period been approved by the data sharing committee for this project?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Please explain the reason for delaying release (e.g., pre-existing collaborative agreement)</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Study Visibility</name>
      <value>Hold</value>
    </descriptor>
    <descriptor>
      <name>Does this study contain samples that are contaminated with human DNA which must be removed prior to analysis?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Number of gigabases per sample (minimum 0.15)</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>ArrayExpress Accession Number</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>EGA Policy Accession Number</name>
      <value>EGAP00001000021</value>
    </descriptor>
    <descriptor>
      <name>Will you be using WTSI's standard access agreement?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>ENA Study Accession Number</name>
      <value>EGAS00001000090</value>
    </descriptor>
    <descriptor>
      <name>Title</name>
      <value>UK10K whole genome shotgun sequence: ALSPAC cohort</value>
    </descriptor>
    <descriptor>
      <name>Abstract</name>
      <value>The Avon Longitudinal Study of Parents and Children (ALSPAC) is a two-generation prospective study. Pregnant women living in one of three health districts in the former county of Avon with an expected delivery date between April 1991 and December 1992 were eligible to be enrolled in the study, and this formed the intitial point of contact for the development of a large, family based resource.

Detailed information has been collected on the children and the mothers through retrieval of biological materials (e.g. antenatal blood samples, placentas), biological sampling (e.g. collection of cord blood, umbilical cord, milk teeth, hair, toenails, blood and urine), self-administered questionnaires, data extraction from medical notes, linkage to routine information systems and at repeat research clinics.

The ALSPAC samples will be used in a variety of genotyping and sequencing projects. </value>
    </descriptor>
    <descriptor>
      <name>SNP study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the reason for preventing data release?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Alignments in BAM</name>
      <value>true</value>
    </descriptor>
    <descriptor>
      <name>Reason for delaying release</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Do any of the samples in this study contain human DNA?</name>
      <value>Yes</value>
    </descriptor>
    <descriptor>
      <name>Does this study require y chromosome data to be separated from x and autosomal data before archival?</name>
      <value>false</value>
    </descriptor>
    <descriptor>
      <name>SNP parent study ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding data release timing and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>What is the data release strategy for this study?</name>
      <value>managed</value>
    </descriptor>
    <descriptor>
      <name>ENA Project ID</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Comment regarding prevention of data release and approval</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Delay for</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Study name abbreviation</name>
      <value>UK10K_ALS</value>
    </descriptor>
    <descriptor>
      <name>Are all the samples to be used in this study commercially available, unlinked anonymised cell-lines?</name>
      <value>No</value>
    </descriptor>
    <descriptor>
      <name>Study description</name>
      <value>	The UK10K project proposes a series of complementary genetic approaches to find new low-frequency/rare variants contributing to disease phenotypes. These will be based on obtaining the genome-wide sequence of 4000 samples from the TwinsUK and ALSPAC cohorts (at 6x sequence coverage), and the exome sequence (protein-coding regions and related conserved sequence) of 6000 samples selected for extreme phenotypes. Our studies will focus primarily on cardiovascular-related quantitative traits, obesity and related metabolic traits, neurodevelopmental disorders and a limited number of extreme clinical phenotypes that will provide proof-of-concept for future familial trait sequencing. We will directly analyse quantitative traits in the cohorts and the selected traits in the extreme samples, and also use imputation down to 0.1% allele frequency to extend the analyses to further sample sets with genome wide genotype data. In each case we will investigate indels and larger structural variants as well as SNPs, and use statistical methods that combine rare variants in a locus or pathway as well as single-variant approaches.</value>
    </descriptor>
    <descriptor>
      <name>Has this been approved?</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>EGA DAC Accession Number</name>
      <value>EGAC00001000024</value>
    </descriptor>
    <descriptor>
      <name>Policy</name>
      <value></value>
    </descriptor>
    <descriptor>
      <name>Reference Genome</name>
      <value>Homo_sapiens (1000Genomes)</value>
    </descriptor>
    <descriptor>
      <name>Study Type</name>
      <value>Whole Genome Sequencing</value>
    </descriptor>
    <descriptor>
      <name>Faculty Sponsor</name>
      <value>Richard Durbin</value>
    </descriptor>
    <descriptor>
      <name>What sort of study is this?</name>
      <value>genomic sequencing</value>
    </descriptor>
  </descriptors>
</study>
